Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20743137 | 0.88 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTTP53FFAR2RAB9A | |
| SCHEMBL21821311 | 0.88 | NPC1 (0.43) | SMN1; SMN2MAPTTP53FFAR2RAB9A | |
| SCHEMBL30645011 | 0.88 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTTP53FFAR2RAB9A | |
| SCHEMBL20744007 | 0.86 | NPC1 (0.46) | SMN1; SMN2MAPTTP53RAB9ANPC1 | |
| SCHEMBL19283525 | 0.82 | FFAR2 (0.39) | SMN1; SMN2MAPTTP53FFAR2RAB9A | |
| SCHEMBL30645024 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2TP53FFAR2RAB9ANPC1 | |
| SCHEMBL20743140 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2TP53FFAR2RAB9ANPC1 | |
| SCHEMBL19283637 | 0.79 | ITGA5 (0.47) | SMN1; SMN2MAPTRAB9ANPC1HTT | |
| SCHEMBL19283582 | 0.74 | NTRK1 (0.39) | SMN1; SMN2MAPTFFAR2RAB9ANPC1 | |
| SCHEMBL20743990 | 0.73 | NPC1 (0.47) | SMN1; SMN2TP53RAB9ANPC1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274092-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2022-03-15 | — | — | US | disclosed |
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-06-24 | — | — | US | disclosed |
| EP-3419973-B1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNN2, KCNN1 | SMN1; SMN2 1510/4885MAPT 3651/4885TP53 4852/4885 |
| US-11274092-B2 | Potassium channel inhibitors | KCNJ2, KCNJ11, KCNJ1 | SMN1; SMN2 1525/4885MAPT 3351/4885TP53 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.